Cell-free Protein Synthesis Market worth $308.9 million by 2030 with 7.3% CAGR | MarketsandMarkets Trademark

The cell-free protein synthesis market is projected to reach USD 308.9 million by 2030, growing from USD 217.2 million in 2025, with a CAGR of 7.3%.
The global Cell-free Protein Synthesis Market [https://www.marketsandmarkets.com/Market-Reports/cell-free-protein-synthesis-market-141393235.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=cellfreeproteinsynthesismarket], valued at US$203.9 million in 2024, stood at US$217.2 million in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2030, culminating in a forecasted valuation of US$308.9 million by the end of the period. This growth is driven by the rising need to efficiently produce toxic and challenging proteins, the integration of AI/ML technologies, and increased adoption of reconstituted CFPS systems. Growth drivers include expanded applications in research, biopharmaceutical manufacturing, and diagnostics, as well as advances in high-throughput, automation, and scalable platforms. These innovations enhance the reliability, affordability, and versatility of cell-free systems for complex protein production. The market also offers promising opportunities in commercial validation, vaccine development, synthetic biology, biosensor creation, and expanding into personalized medicine and therapeutic proteins. Adoption among research labs and pharmaceutical firms is rising, thanks to CFPS's flexibility and rapid protein synthesis without live cells, which supports quick prototyping and faster R&D cycles.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=141393235 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=141393235&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=cellfreeproteinsynthesismarket]

By offerings, the cell-free protein synthesis market is divided into products (such as expression systems, reagents, and instruments) and services. CFPS services are expected to grow the fastest in the CFPS market during the forecast period, due to their ability to deliver customized protein expression, lower infrastructure and operational costs for users, and support high-throughput research and drug discovery projects. The demand for services is also increasing because more pharmaceutical and biotechnology companies, academic researchers, and diagnostic developers are outsourcing, relying on specialized providers for quick turnaround, technical expertise, and scalable production. This trend is further supported by the need for flexible, project-based solutions that give clients access to advanced CFPS technologies without the burden of maintaining in-house capabilities.

By Method, the cell-free protein synthesis market is categorized by method into coupled transcription-translation (Tx/Tl) and translation-only expression approaches. In 2024, coupled transcription-translation (Tx/Tl) held the largest market share because of its ability to streamline protein production by combining transcription and translation in one reaction. This method greatly cuts down on time and labor, allowing for quick protein synthesis directly from DNA templates. The Tx/Tl technique is favored for its high efficiency, versatility in producing various proteins, and suitability for high-throughput applications like enzyme engineering, pathway prototyping, and therapeutic development. Its adaptability to both prokaryotic and eukaryotic systems also make it appealing for research, diagnostics, and industrial biotech, fuelling its leading position in the CFPS market.

By geography, the market for cell-free protein synthesis is categorized by regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, North America dominated the global market, driven by its strong research infrastructure, high biotech investments, presence of leading CFPS firms, and widespread use of advanced protein synthesis methods across academic, pharmaceutical, and industrial fields. Meanwhile, Asia-Pacific is projected to experience the fastest growth, aided by increasing government funding for biotech and life sciences, rapid development in pharmaceutical and synthetic biology sectors, and the expanding use of cell-free protein synthesis in both research and industry. Countries like China, Japan, South Korea, and India are heavily investing in R&D and infrastructure, attracting international companies and opening up substantial opportunities for market growth.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=141393235 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=141393235&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=cellfreeproteinsynthesismarket]

Key players in the cell-free protein synthesis market include Promega Corporation (US), New England Biolabs (US), Thermo Fisher Scientific Inc. (US), Takara Bio (Japan), and Genscript (US), among others.

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cellfree-protein-synthesis-market-worth-3089-million-by-2030-with-73-cagr-marketsandmarkets]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cell-free-protein-synthesis-market-141393235.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.